Clinical Trials Logo

Refractory clinical trials

View clinical trials related to Refractory.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00752518 Completed - Multiple Myeloma Clinical Trials

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Start date: May 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety/tolerability and determine the Japanese recommended dose (RD) of bortezomib administered as a once-daily intravenous bolus twice weekly for 2 consecutive weeks(Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 to 21) in Japanese patients with relapsed or refractory multiple myeloma.